Monday 09 / November / 2026
Muscat: The University Medical City, represented by the Sultan Qaboos Comprehensive Cancer Care and Research Centre, concluded the national training program in the field of alpha and beta particle-emitting radionuclide therapies, which was implemented in cooperation with the International Atomic Energy Agency (IAEA).
The program aimed at qualifying national cadres and developing their expertise in utilizing modern oncology treatment technologies.
The five-day program focused on imparting advanced knowledge and skills in the diagnostic and therapeutic applications of radionuclides to participants working in the specialties of nuclear medicine, radiopharmacy, and medical physics, through scientific lectures, workshops, and interactive sessions, with the participation of international experts and specialists from the Sultanate of Oman.
The program's themes encompassed the latest therapeutic applications of Lutetium-177 and Actinium-225 isotopes, patient selection criteria, quantitative imaging techniques, radiation protection, dosimetric measurements, and side-effect management, as well as mechanisms for preparing radiopharmaceuticals, ensuring their quality, and safe operation requirements for treatment facilities.
The program witnessed the discussion of a number of clinical cases and practical applications, alongside the exchange of expertise and experiences between participants and international experts, contributing to the development of professional practices and raising the readiness of national cadres to handle advanced therapeutic technologies.
The implementation of the program comes within the framework of the University Medical City's directions aimed at expanding the scope of nuclear medicine services and developing specialized radiation therapies through building national capabilities, localizing expertise, and strengthening international partnerships, thereby contributing to improving the level of healthcare provided to cancer patients in the Sultanate of Oman.
